The Neuroimmunology of Schizophrenia

키워드

참고문헌 (189)

1. Tandon R, "Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology", Schizophr Res, 102, pp.1~18 (2008)
2. Perälä J, "Lifetime prevalence of psychotic and bipolar I disorders in a general population", Arch Gen Psychiatry, 64, pp.19~28 (2007)
3. Liddle PF, "The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy", Br J Psychiatry, 151, pp.145~151 (1987)
4. Bellak L, "Schizophrenia: a review of the syndrome" (1958), Logos Press
5. Harrison PJ, "Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence", Mol Psychiatry, 10, pp.40~68 (2005)
6. Jaaro-Peled H, "Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1", Trends Neurosci, 32, pp.485~495 (2009)
7. Lewis DA, "Schizophrenia as a disorder of neurodevelopment", Annu Rev Neurosci, 25, pp.409~432 (2002)
8. Lewis DA, "Catching up on schizophrenia: natural history and neurobiology", Neuron, 28, pp.325~334 (2000)
9. Mueser KT, "Schizophrenia", Lancet, 363, pp.2063~2072 (2004)
10. Sawa A, "Schizophrenia: diverse approaches to a complex disease", Science, 296, pp.692~695 (2002)
11. Weinberger DR, "Implications of normal brain development for the pathogenesis of schizophrenia", Arch Gen Psychiatry, 44, pp.660~669 (1987)
12. Carlsson A, "The current status of the dopamine hypothesis of schizophrenia", Neuropsychopharmacology, 1, pp.179~186 (1988)
13. Kim JS, "Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia", Neurosci Lett, 20, pp.379~382 (1980)
14. Olney JW, "NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia", Neuropsychopharmacology, 13, pp.335~345 (1995)
15. Koran LM, "Gamma-Aminobutyric-acid deficiency in schizophrenia", Lancet, 2, pp.1025~ (1976)
16. Lewis DA, "Cortical inhibitory neurons and schizophrenia", Nat Rev Neurosci, 6, pp.312~324 (2005)
17. Ingvar DH, "Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia", Acta Psychiatr Scand, 50, pp.425~462 (1974)
18. Wolkin A, "Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography", Am J Psychiatry, 142, pp.564~571 (1985)
19. Andreasen N, "Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging study", Arch Gen Psychiatry, 43, pp.136~144 (1986)
20. Murray RM, "Is schizophrenia a neurodevelopmental disorder?", Br Med J, 295, pp.681~682 (1987)
21. Zubin J, "Vulnerability-a new view of schizophrenia", J Abnorm Psychol, 86, pp.103~126 (1977)
22. Lin A, "The inflammatory response system in treatmentresistant schizophrenia: increased serum interleukin-6", Schizophr Res, 32, pp.9~15 (1998)
23. Rothermundt M, "Review of immunological and immunopathological findings in schizophrenia", Brain Behav Immun, 15, pp.319~339 (2001)
24. Fan X, "Inflammation and schizophrenia", Expert Rev Neurother, 7, pp.789~796 (2007)
25. Potvin S, "Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review", Biol Psychiatry, 63, pp.801~808 (2008)
26. Drexhage RC, "The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder", Expert Rev Neurother, 10, pp.59~76 (2010)
27. Johnstone EC, "The occurrence of organic disease of possible or probable aetiological significance in a population of 268 cases of first episode schizophrenia", Psychol Med, 17, pp.371~379 (1987)
28. Misra PC, "Encephalitis presenting as acute schizophrenia", Br Med J, 1, pp.532~533 (1971)
29. Weinstein EA, "Encephalitis with a clinical picture of schizophrenia", J Mt Sinai Hosp N Y, 21, pp.341~354 (1955)
30. Heidrich R, "Catatoniform state in the course of a leuko-encephalitis", Psychiatr Neurol Med Psychol (Leipz), 13, pp.241~247 (1961)
31. Raskin DE, "Herpes encephalitis with catatonic stupor", Arch Gen Psychiatry, 31, pp.544~546 (1974)
32. Kim CH, "Encephalitis with catatonic schizophrenic symptoms", IMJ Ill Med J, 138, pp.503~507 (1970)
33. Brown AS, "In utero infection and adult schizophrenia", Ment Retard Dev Disabil Res Rev, 8, pp.51~57 (2002)
34. Eaton WW, "Association of schizophrenia and autoimmune diseases: linkage of Danish national registers", Am J Psychiatry, 163, pp.521~528 (2006)
35. Müller N, "Cellular immunity in schizophrenic patients before and during neuroleptic treatment", Psychiatry Res, 37, pp.147~160 (1991)
36. Smith RS, "The immune system is a key factor in the etiology of psychosocial disease", Med Hypotheses, 34, pp.49~57 (1991)
37. Stevens JR, "Neuropathology of schizophrenia", Arch Gen Psychiatry, 39, pp.1131~1139 (1982)
38. Serhan CN, "Resolution of inflammation: the beginning programs the end", Nat Immunol, 6, pp.1191~1197 (2005)
39. Majno G, "The healing hand: man and wound in the ancient world" (1975), Harvard University Press
40. Steinke JW, "3. Cytokines and chemokines", J Allergy Clin Immunol, 117(2 Suppl Mini-Primer), pp.S441~S445 (2006)
41. Curfs JH, "A primer on cytokines: sources, receptors, effects, and inducers", Clin Microbiol Rev, 10, pp.742~780 (1997)
42. Simard AR, "Do pathogen exposure and innate immunity cause brain diseases?", Neurol Res, 27, pp.717~725 (2005)
43. Ferrari G, "Epidermal growth factor exerts neuronotrophic effects on dopaminergic and GABAergic CNS neurons: comparison with basic fibroblast growth factor", J Neurosci Res, 30, pp.493~497 (1991)
44. Li Y, "Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway", J Neurosci, 23, pp.1605~1611 (2003)
45. Namba H, "Transforming growth factor alpha attenuates the functional expression of AMPA receptors in cortical GABAergic neurons", Mol Cell Neurosci, 31, pp.628~641 (2006)
46. Namba H, "Transforming growth factor-alpha changes firing properties of developing neocortical GABAergic neurons by down-regulation of voltage-gated potassium currents", Neuroscience, 122, pp.637~646 (2003)
47. Qin L, "Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration", Glia, 55, pp.453~462 (2007)
48. Kronfol Z, "Cytokines and the brain: implications for clinical psychiatry", Am J Psychiatry, 157, pp.683~694 (2000)
49. Raison CL, "Is depression an inflammatory disorder?", Curr Psychiatry Rep, 13, pp.467~475 (2011)
50. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, "Genome-wide association study identifies five new schizophrenia loci", Nat Genet, 43, pp.969~976 (2011)
51. Li T, "51. Li T, Li Z, Chen P, Zhao Q, Wang T, Huang K, et al. Common variants in major histocompatibility complex region and TCF4 gene are significantly associated with schizophrenia in Han Chinese", Biol Psychiatry, 68, pp.671~673 (2010)
52. Stefansson H, "Common variants conferring risk of schizophrenia", Nature, 460, pp.744~747 (2009)
53. International Schizophrenia Consortium, "Common polygenic variation contributes to risk of schizophrenia and bipolar disorder", Nature, 460, pp.748~752 (2009)
54. Shiina T, "The HLA genomic loci map: expression, interaction, diversity and disease", J Hum Genet, 54, pp.15~39 (2009)
55. van Heel DA, "A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21", Nat Genet, 39, pp.827~829 (2007)
56. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), "Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci", Nat Genet, 40, pp.204~210 (2008)
57. Hwang Y, "Gene expression profiling by mRNA sequencing reveals increased expression of immune", inflammationrelated genes in the hippocampus of individuals with schizophrenia, 2013, pp.3, e321~
58. Allen NC, "Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database", Nat Genet, 40, pp.827~834 (2008)
59. Paul-Samojedny M, "Association study of interferon gamma (IFN-γ) +874T", A gene polymorphism in patients with paranoid schizophrenia, 2011, pp.43, 309~315
60. Ozbey U, "The value of interleukin- 12B (p40) gene promoter polymorphism in patients with schizophrenia in a region of East Turkey", Psychiatry Clin Neurosci, 62, pp.307~312 (2008)
61. Ozbey U, "Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey", World J Biol Psychiatry, 10, pp.461~468 (2009)
62. Xu M, "Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population", Schizophr Res, 120, pp.131~142 (2010)
63. Katila H, "Polymorphisms of the interleukin-1 gene complex in schizophrenia", Mol Psychiatry, 4, pp.179~181 (1999)
64. Zanardini R, "Association between IL-1beta -511C", T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia, 2003, pp.37, 457~462
65. Shirts BH, "Association study of IL10, IL1beta, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: suggestive association with rs16944 at IL1beta", Schizophr Res, 88, pp.235~244 (2006)
66. Lencz T, "Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia", Mol Psychiatry, 12, pp.572~580 (2007)
67. Sun S, "Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population", Neurosci Lett, 440, pp.35~37 (2008)
68. Sun S, "A family-based study of the IL3RA gene on susceptibility to schizophrenia in a Chinese Han population", Brain Res, 1268, pp.13~16 (2009)
69. Fillman SG, "Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia", Mol Psychiatry, 18, pp.206~214 (2013)
70. Miller BJ, "Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects", Biol Psychiatry, 70, pp.663~671 (2011)
71. Szuster-Ciesielska A, "Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers", Arch Immunol Ther Exp (Warsz), 52, pp.59~67 (2004)
72. Ghezzi P, "Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice", Eur J Pharmacol, 317, pp.369~376 (1996)
73. Maes M, "Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine", Acta Psychiatr Scand, 89, pp.346~351 (1994)
74. Hinze-Selch D, "In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research", Brain Behav Immun, 15, pp.282~318 (2001)
75. Pollmãcher T, "qSmoking affects plasma-soluble interleukin-2 receptor levels in patients with schizophrenia", Arch Gen Psychiatry, 54, pp.89~90 (1997)
76. Dowlati Y, "A meta-analysis of cytokines in major depression", Biol Psychiatry, 67, pp.446~457 (2010)
77. Johnstone EC, "Cerebral ventricular size and cognitive impairment in chronic schizophrenia", Lancet, 2, pp.924~926 (1976)
78. Reveley AM, "Cerebral ventricular size in twins discordant for schizophrenia", Lancet, 1, pp.540~541 (1982)
79. Andreasen NC, "Brain imaging: applications in psychiatry", Science, 239, pp.1381~1388 (1988)
80. Andreasen NC, "Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities", Arch Gen Psychiatry, 47, pp.35~44 (1990)
81. Andreasen NC, "Ventricular enlargement in schizophrenia evaluated with computed tomographic scanning. Effects of gender, age, and stage of illness", Arch Gen Psychiatry, 47, pp.1008~1015 (1990)
82. Lawrie SM, "Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies", Br J Psychiatry, 172, pp.110~120 (1998)
83. Van Horn JD, "Ventricular enlargement in schizophrenia. A meta-analysis of studies of the ventricle: brain ratio (VBR)", Br J Psychiatry, 160, pp.687~697 (1992)
84. Lawrie SM, "Magnetic resonance imaging of brain in people at high risk of developing schizophrenia", Lancet, 353, pp.30~33 (1999)
85. Erlenmeyer-Kimling L, "Neurobehavioral deficits in offspring of schizophrenic parents: liability indicators and predictors of illness", Am J Med Genet, 97, pp.65~71 (2000)
86. Niemi LT, "Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies", Schizophr Res, 60, pp.239~258 (2003)
87. Harris JM, "Increased prefrontal gyrification in a large high-risk cohort characterizes those who develop schizophrenia and reflects abnormal prefrontal development", Biol Psychiatry, 62, pp.722~729 (2007)
88. Job DE, "Grey matter changes over time in high risk subjects developing schizophrenia", Neuroimage, 25, pp.1023~1030 (2005)
89. Johnstone EC, "Edinburgh high risk study-findings after four years: demographic, attainment and psychopathological issues", Schizophr Res, 46, pp.1~15 (2000)
90. McIntosh AM, "Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis", Biol Psychiatry, 69, pp.953~958 (2011)
91. Harrison PJ, "Brains at risk of schizophrenia", Lancet, 353, pp.3~4 (1999)
92. Ellman LM, "Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8", Schizophr Res, 121, pp.46~54 (2010)
93. Stefansson H, "Neuregulin 1 and susceptibility to schizophrenia", Am J Hum Genet, 71, pp.877~892 (2002)
94. Corfas G, "Neuregulin 1-erbB signaling and the molecular", cellular basis of schizophrenia, 2004, pp.7, 575~580
95. Hall J, "A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms", Nat Neurosci, 9, pp.1477~1478 (2006)
96. Hänninen K, "Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia", Eur Arch Psychiatry Clin Neurosci, 258, pp.10~15 (2008)
97. Fatjó-Vilas M, "Effect of the interleukin-1β gene on dorsolateral prefrontal cortex function in schizophrenia: a genetic neuroimaging study", Biol Psychiatry, 72, pp.758~765 (2012)
98. Papiol S, "Effect of interleukin-1beta gene functional polymorphism on dorsolateral prefrontal cortex activity in schizophrenic patients", Am J Med Genet B Neuropsychiatr Genet, 144B, pp.1090~1093 (2007)
99. Dammann O, "Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn", Pediatr Res, 42, pp.1~8 (1997)
100. Dammann O, "Role of the fetus in perinatal infection and neonatal brain damage", Curr Opin Pediatr, 12, pp.99~104 (2000)
101. Shatrov JG, "Chorioamnionitis and cerebral palsy: a meta-analysis", Obstet Gynecol, 116, pp.387~392 (2010)
102. Roberts GW, "Schizophrenia: a neuropathological perspective", Br J Psychiatry, 158, pp.8~17 (1991)
103. Buka SL, "Maternal cytokine levels during pregnancy and adult psychosis", Brain Behav Immun, 15, pp.411~420 (2001)
104. Brown AS, "Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring", Am J Psychiatry, 161, pp.889~895 (2004)
105. Khandaker G, "Neurologic complications of influenza A(H1N1)pdm09: surveillance in 6 pediatric hospitals", Neurology, 79, pp.1474~1481 (2012)
106. Brown AS, "Prenatal infection and schizophrenia: a review of epidemiologic and translational studies", Am J Psychiatry, 167, pp.261~280 (2010)
107. Brown AS, "Serologic evidence of prenatal influenza in the etiology of schizophrenia", Arch Gen Psychiatry, 61, pp.774~780 (2004)
108. Fellerhoff B, "Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10", Mol Psychiatry, 12, pp.264~272 (2007)
109. Fellerhoff B, "High risk of schizophrenia and other mental disorders associated with chlamydial infections: hypothesis to combine drug treatment and adoptive immunotherapy", Med Hypotheses, 65, pp.243~252 (2005)
110. Hammond CJ, "Parvovirus B19 infection of brain: possible role of gender in determining mental illness and autoimmune thyroid disorders", Med Hypotheses, 69, pp.113~116 (2007)
111. Dalman C, "Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects", Am J Psychiatry, 165, pp.59~65 (2008)
112. Arias I, "Infectious agents associated with schizophrenia: a meta-analysis", Schizophr Res, 136, pp.128~136 (2012)
113. Yolken RH, "Are some cases of psychosis caused by microbial agents? A review of the evidence", Mol Psychiatry, 13, pp.470~479 (2008)
114. Prasad KM, "Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia", Mol Psychiatry, 12, pp.105~113 (2007)
115. Schretlen DJ, "Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia", Schizophr Res, 118, pp.224~231 (2010)
116. Prasad KM, "Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study", Am J Psychiatry, 168, pp.822~830 (2011)
117. Whitford TJ, "Structural abnormalities in the cuneus associated with Herpes Simplex Virus (type 1) infection in people at ultra high risk of developing psychosis", Schizophr Res, 135, pp.175~180 (2012)
118. Prasad KM, "Grey matter changes associated with host genetic variation and exposure to Herpes Simplex Virus 1 (HSV1) in first episode schizophrenia", Schizophr Res, 118, pp.232~239 (2010)
119. Clarke MC, "Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia", Am J Psychiatry, 166, pp.1025~1030 (2009)
120. Meyer U, "Epidemiology-driven neurodevelopmental animal models of schizophrenia", Prog Neurobiol, 90, pp.285~326 (2010)
121. Meyer U, "A review of the fetal brain cytokine imbalance hypothesis of schizophrenia", Schizophr Bull, 35, pp.959~972 (2009)
122. Patterson PH, "Immune involvement in schizophrenia and autism: etiology, pathology and animal models", Behav Brain Res, 204, pp.313~321 (2009)
123. Macêdo DS, "Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: a systematic review", Braz J Med Biol Res, 45, pp.179~186 (2012)
124. Ibi D, "Astroglial IFITM3 mediates neuronal impairments following neonatal immune challenge in mice", Glia, 61, pp.679~693 (2013)
125. Horváth S, "Immune system disturbances in schizophrenia", Biol Psychiatry (2013)
126. Brass AL, "The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus", Cell, 139, pp.1243~1254 (2009)
127. Ransohoff RM, "Microglial physiology: unique stimuli, specialized responses", Annu Rev Immunol, 27, pp.119~145 (2009)
128. Block ML, "Microglia-mediated neurotoxicity: uncovering the molecular mechanisms", Nat Rev Neurosci, 8, pp.57~69 (2007)
129. Bernstein HG, "Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy", Expert Rev Neurother, 9, pp.1059~1071 (2009)
130. Monji A, "Cytokines and schizophrenia: Microglia hypothesis of schizophrenia", Psychiatry Clin Neurosci, 63, pp.257~265 (2009)
131. Bayer TA, "Evidence for activation of microglia in patients with psychiatric illnesses", Neurosci Lett, 271, pp.126~128 (1999)
132. Radewicz K, "Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics", J Neuropathol Exp Neurol, 59, pp.137~150 (2000)
133. Garey L, "When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits", J Anat, 217, pp.324~333 (2010)
134. Wierzba-Bobrowicz T, "Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics", Folia Neuropathol, 43, pp.81~89 (2005)
135. PK11195 positron emission tomography study, "Biol Psychiatry", 2008, 820~822
136. Doorduin J, "Neuroinflammation in schizophrenia-related psychosis: a PET study", J Nucl Med, 50, pp.1801~1807 (2009)
137. Togo T, "Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases", Brain Res, 885, pp.117~121 (2000)
138. Falke E, "Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia", Psychiatry Res, 93, pp.103~110 (2000)
139. Arnold SE, "Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia", Arch Gen Psychiatry, 55, pp.225~232 (1998)
140. Kurumaji A, "Decreases in peripheraltype benzodiazepine receptors in postmortem brains of chronic schizophrenics", J Neural Transm, 104, pp.1361~1370 (1997)
141. Steiner J, "Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization", Acta Neuropathol, 112, pp.305~316 (2006)
142. Dong Y, "Immune function of astrocytes", Glia, 36, pp.180~190 (2001)
143. Donato R, "Intracellular and extracellular roles of S100 proteins", Microsc Res Tech, 60, pp.540~551 (2003)
144. Heizmann CW, "Pathologies involving the S100 proteins and RAGE", Subcell Biochem, 45, pp.93~138 (2007)
145. Rothermundt M, "S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia", Neuropsychopharmacology, 29, pp.1004~1011 (2004)
146. Sorci G, "S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond", Cardiovasc Psychiatry Neurol, 2010 (2010)
147. Rothermundt M, "Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology", Mol Psychiatry, 6, pp.445~449 (2001)
148. Steiner J, "S100B protein in neurodegenerative disorders", Clin Chem Lab Med, 49, pp.409~424 (2011)
149. Steiner J, "Evidence for a wide extra-astrocytic distribution of S100B in human brain", BMC Neurosci, 8, pp.2~ (2007)
150. Steiner J, "S100B serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance", Cardiovasc Psychiatry Neurol, 2010, pp.480707~ (2010)
151. Gonçalves CA, "Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue", Cardiovasc Psychiatry Neurol, 2010, pp.790431~ (2010)
152. Chen SJ, "Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study", Br J Psychiatry, 200, pp.374~380 (2012)
153. Strous RD, "Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited", J Autoimmun, 27, pp.71~80 (2006)
154. Stephan KE, "Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring", Schizophr Bull, 35, pp.509~527 (2009)
155. Javitt DC, "Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions", Int Rev Neurobiol, 78, pp.69~108 (2007)
156. Krystal JH, "Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses", Arch Gen Psychiatry, 51, pp.199~214 (1994)
157. Javitt DC, "Recent advances in the phencyclidine model of schizophrenia", Am J Psychiatry, 148, pp.1301~1308 (1991)
158. Kantrowitz JT, "Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models", Clin Schizophr Relat Psychoses, 4, pp.189~200 (2010)
159. Tanaka S, "Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders", J Neuroimmunol, 141, pp.155~164 (2003)
160. Borda T, "Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction", J Immunol, 168, pp.3667~3674 (2002)
161. Hughes EG, "Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis", J Neurosci, 30, pp.5866~5875 (2010)
162. Dalmau J, "Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies", Lancet Neurol, 7, pp.1091~1098 (2008)
163. Braakman HM, "Pearls & Oy-sters: electroconvulsive therapy in anti-NMDA receptor encephalitis", Neurology, 75, pp.e44~e46 (2010)
164. Dalmau J, "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma", Ann Neurol, 61, pp.25~36 (2007)
165. Tsutsui K, "Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features", BMC Psychiatry, 12, pp.37~ (2012)
166. Zandi MS, "Disease-relevant autoantibodies in first episode schizophrenia", J Neurol, 258, pp.686~688 (2011)
167. Steiner J, "Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis", JAMA Psychiatry, 70, pp.271~278 (2013)
168. Leucht S, "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis", Lancet, 373, pp.31~41 (2009)
169. Whiskey E, "Restarting clozapine after neutropenia: evaluating the possibilities and practicalities", CNS Drugs, 21, pp.25~35 (2007)
170. Merrill DB, "Adverse cardiac effects associated with clozapine", J Clin Psychopharmacol, 25, pp.32~41 (2005)
171. Mouaffak F, "Clozapine-induced serositis: review of its clinical features, pathophysiology and management strategies", Clin Neuropharmacol, 32, pp.219~223 (2009)
172. Leykin I, "Short and long-term immunosuppressive effects of clozapine and haloperidol", Immunopharmacology, 37, pp.75~86 (1997)
173. Song C, "Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist", Schizophr Res, 42, pp.157~164 (2000)
174. Himmerich H, "Impact of antipsychotics on cytokine production in-vitro", J Psychiatr Res, 45, pp.1358~1365 (2011)
175. Milev P, "Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up", Am J Psychiatry, 162, pp.495~506 (2005)
176. Narvaez JM, "Subjective and objective quality of life in schizophrenia", Schizophr Res, 98, pp.201~208 (2008)
177. Tek C, "A five-year followup study of deficit and nondeficit schizophrenia", Schizophr Res, 49, pp.253~260 (2001)
178. Dean OM, "Minocycline: therapeutic potential in psychiatry", CNS Drugs, 26, pp.391~401 (2012)
179. Yrjänheikki J, "A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window", Proc Natl Acad Sci U S A, 96, pp.13496~13500 (1999)
180. Du Y, "Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease", Proc Natl Acad Sci U S A, 98, pp.14669~14674 (2001)
181. Amin AR, "A novel mechanism of action of tetracyclines: effects on nitric oxide synthases", Proc Natl Acad Sci U S A, 93, pp.14014~14019 (1996)
182. Yong VW, "The promise of minocycline in neurology", Lancet Neurol, 3, pp.744~751 (2004)
183. Levkovitz Y, "A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia", J Clin Psychiatry, 71, pp.138~149 (2010)
184. Chaudhry IB, "Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment", J Psychopharmacol, 26, pp.1185~1193 (2012)
185. Miyaoka T, "Minocycline as adjunctive therapy for schizophrenia: an open-label study", Clin Neuropharmacol, 31, pp.287~292 (2008)
186. Lewis DA, "Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature", J Affect Disord, 5, pp.319~332 (1983)
187. Ling MH, "Side effects of corticosteroid therapy. Psychiatric aspects", Arch Gen Psychiatry, 38, pp.471~477 (1981)
188. Sommer IE, "Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis", J Clin Psychiatry, 73, pp.414~419 (2012)
189. Sommer IE, "Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update", Schizophr Bull (2013)

관련 논문AI추천